» Articles » PMID: 18272180

Order-disorder-order Transitions Mediate the Activation of Cholera Toxin

Overview
Journal J Mol Biol
Publisher Elsevier
Date 2008 Feb 15
PMID 18272180
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Cholera toxin (CT) holotoxin must be activated to intoxicate host cells. This process requires the intracellular dissociation of the enzymatic CTA1 domain from the holotoxin components CTA2 and B5, followed by subsequent interaction with the host factor ADP ribosylation factor 6 (ARF6)-GTP. We report the first NMR-based solution structural data for the CT enzymatic domain (CTA1). We show that this free enzymatic domain partially unfolds at the C-terminus and binds its protein partners at both the beginning and the end of this activation process. Deviations from random coil chemical shifts (Delta delta(coil)) indicate helix formation in the activation loop, which is essential to open the toxin's active site and occurs prior to its association with human protein ARF6. We performed NMR titrations of both free CTA1 and an active CTA1:ARF6-GTP complex with NAD(+), which revealed that the formation of the complex does not significantly enhance NAD(+) binding. Partial unfolding of CTA1 is further illustrated by using 4,4'-bis(1-anilinonaphthalene 8-sulfonate) fluorescence as an indicator of the exposed hydrophobic character of the free enzyme, which is substantially reduced when bound to ARF6-GTP. We propose that the primary role of ARF6's allostery is to induce refolding of the C-terminus of CTA1. Thus, as a folded globular toxin complex, CTA1 escapes the chaperone and proteasomal components of the endoplasmic reticulum associated degradation pathway in the cytosol and then proceeds to ADP ribosylate its target G(s)alpha, triggering the downstream events associated with the pathophysiology of cholera.

Citing Articles

Sortase-Modified Cholera Toxoids Show Specific Golgi Localization.

Machin D, Williamson D, Fisher P, Miller V, Arnott Z, Stevenson C Toxins (Basel). 2024; 16(4).

PMID: 38668619 PMC: 11054894. DOI: 10.3390/toxins16040194.


ARF GTPases activate Salmonella effector SopF to ADP-ribosylate host V-ATPase and inhibit endomembrane damage-induced autophagy.

Xu Y, Cheng S, Zeng H, Zhou P, Ma Y, Li L Nat Struct Mol Biol. 2022; 29(1):67-77.

PMID: 35046574 DOI: 10.1038/s41594-021-00710-6.


cAMP-Independent Activation of the Unfolded Protein Response by Cholera Toxin.

Banerjee T, Grabon A, Taylor M, Teter K Infect Immun. 2020; 89(2).

PMID: 33199355 PMC: 7822150. DOI: 10.1128/IAI.00447-20.


Tuning Allostery through Integration of Disorder to Order with a Residue Network.

Wang J, Samanta R, Custer G, Look C, Matysiak S, Beckett D Biochemistry. 2020; 59(6):790-801.

PMID: 31899864 PMC: 7759012. DOI: 10.1021/acs.biochem.9b01006.


Quercetin-3-Rutinoside Blocks the Disassembly of Cholera Toxin by Protein Disulfide Isomerase.

Guyette J, Cherubin P, Serrano A, Taylor M, Abedin F, ODonnell M Toxins (Basel). 2019; 11(8).

PMID: 31382673 PMC: 6722528. DOI: 10.3390/toxins11080458.


References
1.
Hall D, Vander Kooi C, Stasik C, Stevens S, Zuiderweg E, Matthews R . Mapping the interactions between flavodoxin and its physiological partners flavodoxin reductase and cobalamin-dependent methionine synthase. Proc Natl Acad Sci U S A. 2001; 98(17):9521-6. PMC: 55485. DOI: 10.1073/pnas.171168898. View

2.
Lemichez E, Boquet P . To be helped or not helped, that is the question. J Cell Biol. 2003; 160(7):991-2. PMC: 2172775. DOI: 10.1083/jcb.200303032. View

3.
Zhu X, Kim E, Boman A, Hodel A, Cieplak W, Kahn R . ARF binds the C-terminal region of the Escherichia coli heat-labile toxin (LTA1) and competes for the binding of LTA2. Biochemistry. 2001; 40(15):4560-8. DOI: 10.1021/bi002628s. View

4.
Sack D, Sack R, Nair G, Siddique A . Cholera. Lancet. 2004; 363(9404):223-33. DOI: 10.1016/s0140-6736(03)15328-7. View

5.
Hagiwara Y, Kawamura Y, Kataoka K, Rahima B, Jackson R, Komase K . A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. J Immunol. 2006; 177(5):3045-54. PMC: 4469177. DOI: 10.4049/jimmunol.177.5.3045. View